| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/02/2004 | EP1423390A2 Purine inhibitors of phosphodiesterase (pde) 7 |
| 06/02/2004 | EP1423389A1 Pyrazolo-pyridines for the treatment of herpes infections |
| 06/02/2004 | EP1423388A2 2-arylamino-pyrimidines for the treatment of gsk3-related disorders |
| 06/02/2004 | EP1423386A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors |
| 06/02/2004 | EP1423384A1 Pyridine derivatives as raf kinase inhibitors |
| 06/02/2004 | EP1423382A2 Pyrazole-derived kinase inhibitors and uses thereof |
| 06/02/2004 | EP1423381A1 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 06/02/2004 | EP1423380A1 Pyrazole-derived kinase inhibitors and uses thereof |
| 06/02/2004 | EP1423378A1 Aminopyrrole compounds as antiinflammatory agents |
| 06/02/2004 | EP1423376A1 Bicyclic compound, production and use thereof |
| 06/02/2004 | EP1423375A2 Ascorbic acid derivatives, methods of synthesis and pharmaceutical use thereof |
| 06/02/2004 | EP1423370A1 Fxr nr1h4 nuclear receptor binding compounds |
| 06/02/2004 | EP1423368A1 Urea and thiourea derivatives as non-nucleoside reverse transcriptase inhibitors |
| 06/02/2004 | EP1423367A1 Solvates of lercanidipine hydrochloride and new crystalline forms of lercanidipine hydrochloride |
| 06/02/2004 | EP1423366A1 Cyclopenta b ! indole derivatives as spla2 inhibitors |
| 06/02/2004 | EP1423364A1 Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| 06/02/2004 | EP1423363A1 Oral antidiabetic agents |
| 06/02/2004 | EP1423362A1 New mandelic acid derivatives and their use as thrombin inhibitors |
| 06/02/2004 | EP1423359A1 C2-disubstituted indane-1-ones and their derivatives, method for their production and their use as medicaments |
| 06/02/2004 | EP1423358A1 Polysubstituted indan-1-ol systems, method for the production and use thereof as drugs |
| 06/02/2004 | EP1423357A2 Urea derivatives with antiproteolytic activity |
| 06/02/2004 | EP1423356A2 Novel aminobenzoephenones |
| 06/02/2004 | EP1423353A1 Substituted octahydrophenanthrene compounds and their use as nmda antagonists |
| 06/02/2004 | EP1423169A2 Potentiator composition comprising a terpene for enhancing the therapeutical effect of antitumoral agents in the treatment of cancer |
| 06/02/2004 | EP1423168A2 Pharmaceutical composition comprising gabapentin or an analogue thereof and an $g(a)-aminoamide and its analgesic use |
| 06/02/2004 | EP1423167A1 Method for treating alzheimer's disease using quinaldoyl-amine derivatives of oxo- and hydroxy-substituted hydrocarbons |
| 06/02/2004 | EP1423166A2 Non-peptide ccr1 receptor antagonists for the treatment of progressive renal fibrosis |
| 06/02/2004 | EP1423165A2 Intravaginal administration of an aromatase inhibitor for the treatment of oestrogen-dependent proliferative disorders |
| 06/02/2004 | EP1423147A1 Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| 06/02/2004 | EP1423146A1 Composition for treating parkinson's disease containing a cb1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain |
| 06/02/2004 | EP1423145A1 Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain |
| 06/02/2004 | EP1423132A2 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 06/02/2004 | EP1423131A1 Calcium salts with cytotoxic activity |
| 06/02/2004 | EP1423130A1 Antithrombotic compositions comprising low molecular weight heparin and low molecular weight dermatan sulphate |
| 06/02/2004 | EP1423129A1 Therapeutic process for p. aeruginosa infections using macrolide antibiotics |
| 06/02/2004 | EP1423128A2 Methods for the treatment of chronic pain anc compositions therefor |
| 06/02/2004 | EP1423127A1 Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors |
| 06/02/2004 | EP1423126A2 Treatment of hyperproliferative conditions of body surfaces |
| 06/02/2004 | EP1423125A1 Use of non-feminizing estrogens as retinoprotective agents for the treatment of glaucoma |
| 06/02/2004 | EP1423124A2 Lyophilized formulation comprising olanzapine |
| 06/02/2004 | EP1423123A1 Tetracyclic indole derivatives as 5-ht receptor ligands |
| 06/02/2004 | EP1423122A2 Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
| 06/02/2004 | EP1423121A1 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases |
| 06/02/2004 | EP1423120A1 2h-phthalazin-1-ones and methods for use thereof |
| 06/02/2004 | EP1423119A1 Heterobicycles fkbp-ligands |
| 06/02/2004 | EP1423118A1 Method and composition for treatment of cancer |
| 06/02/2004 | EP1423117A1 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors |
| 06/02/2004 | EP1423116A1 Method of treating alcoholism or alcohol abuse |
| 06/02/2004 | EP1423115A2 Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| 06/02/2004 | EP1423114A2 Method and compositions for treating migraines |
| 06/02/2004 | EP1423113A1 Nr1h4 nuclear receptor binding compounds |
| 06/02/2004 | EP1423112A1 A combination of quetiapine and zolmitriptan |
| 06/02/2004 | EP1423111A1 Fxr nr1h4 nuclear receptor binding compounds |
| 06/02/2004 | EP1423110A2 Cbi analogues of cc-1065 and the duocarmycins |
| 06/02/2004 | EP1423109A2 Compositions comprising pectin and ascorbic acid |
| 06/02/2004 | EP1423108A1 C-2' methylated derivatives of paclitaxel for use as antitumour agents |
| 06/02/2004 | EP1423107A2 Fatty alcohol drug conjugates |
| 06/02/2004 | EP1423106A1 Arylsulfonyl derivatives with 5-ht 6 receptor affinity |
| 06/02/2004 | EP1423105A2 Combinations of dmxaa and other anti-cancer agents |
| 06/02/2004 | EP1423104A1 Combination therapy for the treatment of neurological disorders |
| 06/02/2004 | EP1423102A1 Plaster for the treatment of dysfunctions and disorders of nail growth |
| 06/02/2004 | EP1423100A1 Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole |
| 06/02/2004 | EP1423099A1 A new extended release oral dosage form |
| 06/02/2004 | EP1423098A1 A new extended release oral dosage form |
| 06/02/2004 | EP1423095A1 Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 06/02/2004 | EP1423094A2 A new method |
| 06/02/2004 | EP1423092A2 Functional powders for oral delivery |
| 06/02/2004 | EP1423089A1 Cosmetic and/or pharmaceutical preparations containing an extract from pterocarpus marsupium |
| 06/02/2004 | EP1423081A2 Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints |
| 06/02/2004 | EP1423080A2 Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors |
| 06/02/2004 | EP1423008A2 Highly crosslinked biocidal polystyrene hydantoin particles |
| 06/02/2004 | EP1423006A1 Agonists and antagonists of 5h 3?-like receptors of invertebrate s as pesticides |
| 06/02/2004 | EP1326613B1 Use of substituted imidazo 1,2-a]pyridine-, imidazo [1,2-a]pyrimidine and imidazo [1,2-a]pyrazine-3-yl-amine derivatives for producing nos-inhibiting medicaments |
| 06/02/2004 | EP1274405B1 Transdermal or transmucosal dosage forms with a nicotine-containing active substance combination for smoker disintoxication |
| 06/02/2004 | EP1267832B1 SELF EMULSIFYING DRUG DELIVERY SYSTEM, wherein the fatty agent is optional |
| 06/02/2004 | EP1265623B1 Pharmaceutical compositions including alginates |
| 06/02/2004 | EP1259510B1 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| 06/02/2004 | EP1244614B1 Tryptase inhibitors |
| 06/02/2004 | EP1214589B1 Method and device for detecting and isolating pharmacological compounds being contained in substance mixtures |
| 06/02/2004 | EP1204662B1 Azaindoles having serotonin receptor affinity |
| 06/02/2004 | EP1182202B1 Aminomethylpyrrolidine derivatives having aromatic substituents |
| 06/02/2004 | EP1171203B1 Medicaments containing doxazosin-mesylate of crystalline modification d |
| 06/02/2004 | EP1171113B1 Compounds useful as phosphotyrosine mimics |
| 06/02/2004 | EP1164865B1 Method for selectively altering body fat level, feed efficiency, or weight gain |
| 06/02/2004 | EP1156795B1 Use of succinic acid or salts thereof and method of treating insulin resistance |
| 06/02/2004 | EP1143971B1 Substituted 1-(piperidin-4-yl)-3-(aryl)-isothioureas, their preparation and therapeutic use |
| 06/02/2004 | EP1123097B1 Pharmaceutical composition containing decursin |
| 06/02/2004 | EP1114032B1 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors |
| 06/02/2004 | EP1100344B1 Chitosan-containing liquid compositions and methods for their preparation and use |
| 06/02/2004 | EP1098635B1 Enteric coated pharmaceutical tablet containing didanosine |
| 06/02/2004 | EP1068210B1 Process for the production of purine derivatives |
| 06/02/2004 | EP1063978B1 Method of treating neuroma pain |
| 06/02/2004 | EP1056445B1 Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent |
| 06/02/2004 | EP1039900B1 Pharmaceutical composition containing sibutramine and orlistat |
| 06/02/2004 | EP1007008B1 Compositions for treating pulmonary disorders using optically pure (s)-salmeterol |
| 06/02/2004 | EP0959874B1 High dose liposomal aerosol formulations |
| 06/02/2004 | EP0948965B1 Stable medicinal compositions containing 4,5-epoxymorphinane derivatives |
| 06/02/2004 | EP0891376B1 Antifungal peptides from scleroderma texense |
| 06/02/2004 | EP0839034B1 Method of treating colonic adenomas |
| 06/02/2004 | EP0828500B1 Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast |